Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Mar 13, 2026
Why Is Ulta Beauty (ULTA) Stock Down -8.30% Today?

Why Is Ulta Beauty (ULTA) Stock Down -8.30% Today?

Key Takeaways

  • ULTA shares are declining sharply in premarket trading on March 13, 2026, extending losses that began after the company's earnings release after the close on March 12 — with the stock down approximately 8.3% in premarket, building on a -4.28% decline during the regular session on March 12
  • The primary catalyst is fiscal 2026 earnings guidance that fell short of Wall Street expectations, with the company projecting diluted EPS of $28.05–$28.55 against analyst consensus of approximately $28.58
  • While Q4 revenue beat estimates — net sales came in at $3.90 billion vs. the $3.83 billion consensus — Q4 EPS of $8.01 missed some estimates, fueling disappointment
  • Ulta's fiscal 2026 same-store sales growth forecast of 2.5%–3.5% trailed Street expectations of up to 3.5%, signaling a potential deceleration in comparable sales momentum
  • Sector sentiment and a risk-off tone in broader markets are amplifying the sell-off in premarket hours
  • Traders are closely watching whether the stock finds support near key technical levels following the post-earnings gap down

Opening Summary

Ulta Beauty, Inc. (ULTA) is the largest specialty beauty retailer in the United States, operating more than 1,400 stores and offering a broad assortment of cosmetics, skincare, fragrance, and salon services. Shares closed the regular session on March 12 at $624.70, down 4.28% from the prior close of $646.29, before plunging a further ~8% in after-hours trading following the company's Q4 fiscal 2025 earnings release. As of premarket trading on March 13, ULTA is indicated down approximately 8.3% from its March 12 close, putting the combined two-session drawdown firmly in double digits. The immediate trigger is a combination of a bottom-line earnings miss and below-consensus full-year guidance that rattled investor confidence.

Earnings Results: A Mixed Report

Ulta Beauty's fiscal Q4 (ending January 31, 2026) delivered a revenue beat, with net sales rising 11.8% year-over-year to $3.90 billion, topping analyst estimates of approximately $3.83 billion. The top-line performance was aided by comparable store sales strength, the expansion of new locations, and the contribution from the acquisition of British retailer Space NK. However, diluted earnings per share came in at $8.01, narrowly missing some estimates, while the company ended the quarter with $424.2 million in cash and merchandise inventories of $2.2 billion.

Guidance Disappointment: The Core Catalyst

The real blow to ULTA stock came from the company's fiscal 2026 outlook, which underwhelmed investors on multiple dimensions. Management guided for net sales growth of 6%–7% and diluted EPS of $28.05–$28.55, with the midpoint of $28.30 falling below the analyst consensus midpoint of approximately $28.40–$28.58. Same-store sales growth is projected at 2.5%–3.5%, suggesting a moderation from the pace seen in fiscal 2025. Capital expenditure guidance of $400–$450 million was roughly in line with prior-year spending, offering little incremental positive signal.

Market Context and Trading Activity

The regular session on March 12 saw ULTA already trading under pressure ahead of the after-hours print, closing at $624.70 — a level that already reflected some pre-announcement repositioning. After-hours volume surged as traders reacted to the guidance, with the stock falling roughly 8–10% in extended trading. The premarket move on March 13 confirms that selling pressure has not abated overnight. Broader retail sector peers are being monitored for sympathy moves, and the stock is now trading well below its recent trading range, raising questions about near-term technical support. With 17 of 28 analysts still rating ULTA a "Buy" or higher and an average 12-month price target of $701.50, the gap between the current price and consensus target may attract longer-term buyers, but near-term momentum is clearly negative.

Trending AI Robots

For traders looking to navigate volatile sessions like the one ULTA is experiencing, Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing AI trading bots under current market conditions. Tickeron operates hundreds of bots spanning thousands of tickers, varying by strategy, timeframe, risk profile, and performance metrics — but only the strongest performers are surfaced in the Trending section. Whether you prefer momentum-driven strategies, mean-reversion approaches, or sector-specific plays, the Trending AI Robots page provides a live, performance-filtered starting point. Traders seeking a data-driven edge in fast-moving markets may find it a valuable resource to explore.

What Comes Next for ULTA

Looking ahead, investors will be watching whether ULTA management provides additional clarity on the fiscal 2026 growth deceleration during post-earnings analyst calls and conferences. The integration of Space NK and its contribution to international revenue will be a key metric to monitor in coming quarters. Analysts with "Buy" ratings may reassess their price targets in light of the revised guidance, potentially triggering a round of estimate cuts. Macro conditions — including consumer spending trends, inflationary pressures on discretionary retail, and competitive dynamics from mass-market and direct-to-consumer beauty brands — remain ongoing headwinds the market will be scrutinizing. Any commentary on promotional activity, gross margin trajectory, and new store productivity will be central to the investment thesis going forward.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: ULTA

ULTA in upward trend: 10-day moving average broke above 50-day moving average on July 24, 2026

The 10-day moving average for ULTA crossed bullishly above the 50-day moving average on July 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 14, 2026. You may want to consider a long position or call options on ULTA as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ULTA moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ULTA advanced for three days, in of 316 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 267 cases where ULTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ULTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ULTA broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ULTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.985) is normal, around the industry mean (5.566). P/E Ratio (20.220) is within average values for comparable stocks, (35.989). Projected Growth (PEG Ratio) (1.873) is also within normal values, averaging (1.553). ULTA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (1.894) is also within normal values, averaging (1.106).

Notable companies

The most notable companies in this group are Ulta Beauty (NASDAQ:ULTA), Best Buy Company (NYSE:BBY), Tractor Supply Co (NASDAQ:TSCO), Five Below (NASDAQ:FIVE), GameStop Corp (NYSE:GME), Bath & Body Works (NYSE:BBWI), RH (NYSE:RH), 1-800-FLOWERS.COM (NASDAQ:FLWS).

Industry description

The specialty stores sector includes companies dedicated to the sale of retail products focused on a single product category, such as clothing, carpet, books, or office supplies. A specialty store could face intense competition from big-box departmental chains, and therefore offering an adequate collection of the product type it specializes in is key in maintaining/growing its market.

Market Cap

The average market capitalization across the Specialty Stores Industry is 4.63B. The market cap for tickers in the group ranges from 4.65K to 52.32B. ANCTF holds the highest valuation in this group at 52.32B. The lowest valued company is SIMPQ at 4.65K.

High and low price notable news

The average weekly price growth across all stocks in the Specialty Stores Industry was 3%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was -7%. LESL experienced the highest price growth at 53%, while ABLV experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Specialty Stores Industry was 32%. For the same stocks of the Industry, the average monthly volume growth was 35% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 58
Price Growth Rating: 54
SMR Rating: 64
Profit Risk Rating: 88
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
ULTA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company that retails cosmetics and other personal care products

Industry SpecialtyStores

Profile
Details
Industry
Specialty Stores
Address
1000 Remington Boulevard
Phone
+1 630 410-4800
Employees
56000
Web
https://www.ulta.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.